---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-033729"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:39:32.241464+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Eton Pharma awarded second patent for ET-400; PDUFA target Feb 28, 2025

## Summary
- USPTO granted U.S. Patent No. 12,133,914 for ET-400 (liquid hydrocortisone), expiring 2043.
- Second patent for ET-400; first patent (US 11,904,046) obtained in February 2024.
- Additional U.S. patent application for ET-400 remains under review.
- FDA NDA accepted with PDUFA target action date of February 28, 2025.
- If approved, ET-400 would be the only FDA-approved liquid hydrocortisone formulation.

## SEC filing metadata
- accession: 0001437749-24-033729
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774924033729/0001437749-24-033729-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774924033729/eton20241105_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-033729
- JSON: https://secwatch.observer/filing/0001437749-24-033729.json
- Plain text: https://secwatch.observer/filing/0001437749-24-033729.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.